Valuation: MicroPort NeuroScientific Corporation

Capitalization 4.61B 5.34B 681M 591M 542M 511M 950M 64.67B 967M 6.45B 2.5B 31.4B 2.56B 2.5B 109B P/E ratio 2026 *
19.1x
P/E ratio 2027 * 16.7x
Enterprise value 4.61B 5.34B 681M 591M 542M 511M 950M 64.67B 967M 6.45B 2.5B 31.4B 2.56B 2.5B 109B EV / Sales 2026 *
5.27x
EV / Sales 2027 * 4.57x
Free-Float
54.82%
Yield 2026 *
2.12%
Yield 2027 * 2.37%
06-03 MicroPort NeuroScientific Corporation Approves Final Dividend for the Year Ended 31 December 2025 CI
05-29 MicroPort NeuroScientific Partners With OYMotion on Brain-Computer Interface Technology; Shares Jump 5% MT
05-26 MicroPort Neuro Unit Wins US FDA Marketing Approval for Embolization System MT
05-25 Microport Neuroscientific says FDA approves Numentm Helia coil for marketing RE
04-28 MicroPort NeuroScientific Corporation commences an Equity Buyback Plan for 57,553,156 shares, representing 10% of its issued share capital., under the authorization approved on June 27, 2025. CI
04-28 Biodlink International Company Limited Announces Changes in Executives and Board Committee, Effective from 29 April 2026 CI
03-25 MicroPort NeuroScientific posts FY profit attributable RMB184.5 million RE
03-25 MicroPort NeuroScientific Corporation Proposes Final Ordinary Dividend for the Year Ended 31 December 2025, Payable on 21 August 2026 CI
03-25 MicroPort NeuroScientific Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-18 MicroPort NeuroTech's APOLLO Dream Stent System Gets US FDA's Breakthrough Device Designation MT
03-18 MicroPort NeuroScientific says FDA grants breakthrough device designation to Apollo Dream Rapamycin stent system RE
03-18 MicroPort NeuroScientific Corporation Announces Apollo Dream Rapamycin Target Eluting Stent System Granted FDA Breakthrough Device Designation CI
12-29 MicroPort NeuroScientific Corporation Announces Board and Committee Changes, Effective from December 29, 2025 CI
1 day-1.28%
1 week+3.35%
Current month+0.65%
1 month-10.70%
3 months-11.81%
6 months-12.89%
Current year-14.89%
1 week 9.11
Extreme 9.11
9.58
1 month 8.62
Extreme 8.62
10.59
Current year 8.62
Extreme 8.62
14.53
1 year 8.62
Extreme 8.62
19.06
3 years 6.21
Extreme 6.21
19.06
5 years 6.21
Extreme 6.21
26.8
10 years 6.21
Extreme 6.21
26.8
Manager TitleAgeSince
Chief Executive Officer 50 -
Director of Finance/CFO 48 31/05/2018
Chief Tech/Sci/R&D Officer 62 31/12/2023
Director TitleAgeSince
Director/Board Member 50 01/11/2020
Director/Board Member 61 01/11/2020
Director/Board Member 45 18/11/2021
Date Insider Type Main position Quantity % Market Cap.
03-31Other

Chief Executive Officer

247,000 0.0422%
03-30Other 30,067 0.0051%
05/05/25Other

Chief Executive Officer

253,000 0.0438%
Change 5d. change 1-year change 3-years change Capi.($)
-1.28%+3.35%-25.56%-31.61% 689M
+1.48%-0.64%-20.10%+9.83% 115B
+1.28%+3.24%+5.96%-5.13% 12.99B
+2.72%+17.35%+37.42%+101.22% 7.14B
+1.21%-0.73%-44.99%-69.66% 4.35B
+1.43%-0.17%+5.31%+16.69% 2.41B
-0.69%-3.92%+9.74%-9.26% 1.77B
+0.24%-3.75%-26.62%-24.28% 1.63B
+2.62%+13.57%+207.86%+148.06% 1.36B
Average +1.00%+2.17%+16.56%+15.10% 16.42B
Weighted average by Cap. +1.47%-0.87%-12.99%+11.18%

Financials

2026 *2027 *
Net sales 874M 1.01B 129M 112M 103M 96.83M 180M 12.27B 183M 1.22B 475M 5.96B 485M 475M 20.71B 1.01B 1.17B 149M 129M 119M 112M 208M 14.16B 212M 1.41B 548M 6.88B 560M 548M 23.91B
Net income 238M 276M 35.18M 30.54M 28.01M 26.37M 49.05M 3.34B 49.94M 333M 129M 1.62B 132M 129M 5.64B 276M 320M 40.8M 35.41M 32.48M 30.58M 56.88M 3.87B 57.91M 386M 150M 1.88B 153M 150M 6.54B
Net Debt - -
Logo MicroPort NeuroScientific Corporation
MicroPort NeuroScientific Corp is a company mainly engaged in the research, development and manufacturing of neuro-interventional medical devices. The products cover three areas of cerebrovascular disease, including hemorrhagic stroke, cerebral atherosclerotic stenosis and acute ischemic stroke. The hemorrhagic stroke products mainly include NUMEN coil, NUMEN Silk three dimensional (3D) electronically detachable coil, Nufairy absorbable embolization coil and Tubridge flow-diverting stent. The intracranial atherosclerotic stenosis products mainly include APOLLO intracranial stent, Bridge vertebral artery drug-eluting stent (DES) and Diveer intracranial balloon dilatation catheter. The acute ischemic stroke products mainly include Neurohawk intracranial thrombectomy device, Tigertriever revascularization stent and WAVE-track intracranial aspiration catheter. The products also include auxiliary access devices such as Fastrack microcatheter and U-track intracranial support catheter.
Employees
547
Date Price Change Volume
05/06/26 9.260 $ -1.28% 1,889,000
04/06/26 9.380 $ -0.21% 1,164,000
03/06/26 9.400 $ -0.21% 2,346,519
02/06/26 9.420 $ 0.00% 1,219,000
01/06/26 9.420 $ +2.39% 2,427,000
Trader
-
Investor
Global
-
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
8.006CNY
Average target price
10.98CNY
Spread / Average Target
+37.12%

Annual profits - Rate of surprise